
Group Art Unit: 1636



In the Claims

Please cancel claims 1-32 and 33-50 without prejudice.

- 51. (new) A purified preparation of an antibody, or an antigen binding domain thereof, which is specifically immunoreactive with a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
- 52. (new) A polyclonal antibody preparation enriched for antibodies specifically immunoreactive with a mammalian RAPT1 protein.
- 53. (new) A monoclonal antibody composition including a monoclonal antibody, or an antigen binding domain thereof, which is specifically immunoreactive with a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
- 54. (new) A recombinant antibody including an antigen binding domain which is specifically immunoreactive with a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
- 55. (new) The preparation of claim 51, wherein the antibody is immunoreactive with a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
- 56. (new) The preparation of claim 55, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
- 57. (new) The preparation of claim 52, enriched for antibodies immunoreactive with a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
- 58. (new) The preparation of claim 57 wherein the preparation has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
- 59. (new) The preparation of claim 53, wherein the monoclonal antibody is immunoreactive with a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
- 60. (new) The preparation of claim 59, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
- 61. (new) The preparation of claim 54, wherein the antigen binding domain is immunoreactive with a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.